Immatics Biotechnologies GmbH

Immatics N.V.

General information
Immatics Biotechnologies GmbH
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany

Contact person: Harpreet Singh, CEO
Company main phone: +49 (7071) 53970
Company main fax:  +49 (7071) 5397900
Website:  www.immatics.com
Year founded:2000
Source of foundation:Spin-off from university
Name of foundation source:H.G. Rammensee's laboratory at the University of Tübingen, Germany
Corporate description / mission:
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company’s product candidates are adoptive cell therapies and bispecific TCR molecules.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2020
Remarks on ownership / listings
In July 2020, Immatics entered NASDAQ through a business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA; or “Arya”), a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. Today, Immatics N.V. Therefore the company did not file for an IPO.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Cell therapy
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • In-licensing
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:1
Phase I:5
Description of products:
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.
Special IP situation:
The XPRESIDENT technology is protected by granted patents and patent applications.
Technology used:
XPRESIDENT™
XCEPTOR®
Financing details
Market cap. / valuation:EUR 705.21M
Collaborations & Clients
Partnering strategy / collaborations:
Amgen
MDACC
MorphoSys
Roche
Genmab
X